Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Kuwana

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Cancer Immunology, Immunotherapy : CII|June 1, 1993
A mouse/human chimeric anti-(ganglioside GD3) antibody with enhanced antitumor activitiesK Shitara, Y Kuwana, K Nakamura, et al.
Biochemical and Biophysical Research Communications|December 31, 1987
Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regionsY Kuwana, Y Asakura, N Utsunomiya, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 1, 1985
Cloning and expression of cDNA for salmon growth hormone in Escherichia coliS Sekine, T Mizukami, T Nishi, et al.
Cancer Research|March 15, 1994
Chimeric anti-ganglioside GM2 antibody with antitumor activityK Nakamura, M Koike, K Shitara, et al.
Neuron|November 22, 2000
Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activityH Kawasaki, K Mizuseki, S Nishikawa, et al.
International Immunology|January 1, 1990
Perforin, a pore-forming protein detectable by monoclonal antibodies, is a functional marker for killer cellsA Kawasaki, Y Shinkai, Y Kuwana, et al.
Experimental Neurology|March 31, 2000
Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeysT Kanda, M J Jackson, L A Smith, et al.
Annals of Neurology|April 18, 1998
Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeysT Kanda, M J Jackson, L A Smith, et al.
Life Sciences|January 1, 1996
Topiramate reduces abnormally high extracellular levels of glutamate and aspartate in the hippocampus of spontaneously epileptic rats (SER)T Kanda, M Kurokawa, S Tamura, et al.
Neurology|December 10, 2003
Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's diseaseHiroshi Kase, S Aoyama, M Ichimura, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Cancer Immunology, Immunotherapy : CII|June 1, 1993
A mouse/human chimeric anti-(ganglioside GD3) antibody with enhanced antitumor activitiesK Shitara, Y Kuwana, K Nakamura, et al.
Biochemical and Biophysical Research Communications|December 31, 1987
Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regionsY Kuwana, Y Asakura, N Utsunomiya, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 1, 1985
Cloning and expression of cDNA for salmon growth hormone in Escherichia coliS Sekine, T Mizukami, T Nishi, et al.
Cancer Research|March 15, 1994
Chimeric anti-ganglioside GM2 antibody with antitumor activityK Nakamura, M Koike, K Shitara, et al.
Neuron|November 22, 2000
Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activityH Kawasaki, K Mizuseki, S Nishikawa, et al.
International Immunology|January 1, 1990
Perforin, a pore-forming protein detectable by monoclonal antibodies, is a functional marker for killer cellsA Kawasaki, Y Shinkai, Y Kuwana, et al.
Experimental Neurology|March 31, 2000
Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeysT Kanda, M J Jackson, L A Smith, et al.
Annals of Neurology|April 18, 1998
Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeysT Kanda, M J Jackson, L A Smith, et al.
Life Sciences|January 1, 1996
Topiramate reduces abnormally high extracellular levels of glutamate and aspartate in the hippocampus of spontaneously epileptic rats (SER)T Kanda, M Kurokawa, S Tamura, et al.
Neurology|December 10, 2003
Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's diseaseHiroshi Kase, S Aoyama, M Ichimura, et al.
Pageof 2